{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:15:14Z","timestamp":1787829314030,"version":"build-2784847793"},"reference-count":66,"publisher":"Japanese Society of Internal Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,1,1]]},"DOI":"10.2169\/internalmedicine.09279-21","type":"journal-article","created":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T22:11:30Z","timestamp":1672524690000},"page":"43-50","source":"Crossref","is-referenced-by-count":6,"title":["The Expanding Spectrum of Autoinflammatory Diseases"],"prefix":"10.2169","volume":"62","author":[{"given":"Kiyoshi","family":"Migita","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Asano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuzo","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. McDermott MF, Aksentijevich I. The autoinflammatory syndromes. Curr Opin Allergy Clin Immunol 2: 511-516, 2002.","DOI":"10.1097\/00130832-200212000-00006"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ombrello MJ. Advances in the genetically complex autoinflammatory diseases. Semin Immunopathol 37: 403-406, 2015.","DOI":"10.1007\/s00281-015-0498-0"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Patel MN, Carroll RG, Galv\u00e1n-Pe\u00f1a S, et al. Inflammasome priming in sterile inflammatory disease. Trends Mol Med 23: 165-180, 2017.","DOI":"10.1016\/j.molmed.2016.12.007"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Lamkanfi M, Vande Walle L, Kanneganti TD. Deregulated inflammasome signaling in disease. Immunol Rev 243: 163-173, 2011.","DOI":"10.1111\/j.1600-065X.2011.01042.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Sanchez GA, de Jesus AA, Goldbach-Mansky R. Monogenic autoinflammatory diseases: disorders of amplified danger sensing and cytokine dysregulation. Rheum Dis Clin North Am 39: 701-734, 2013.","DOI":"10.1016\/j.rdc.2013.08.001"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Soriano A, Verecchia E, Afeltra A, Landolfi R, Manna R. IL-1\u03b2 biological treatment of familial Mediterranean fever. Clin Rev Allergy Immunol 45: 117-130, 2013.","DOI":"10.1007\/s12016-013-8358-y"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Berteau F, Rouviere B, Delluc A, et al. Autosomic dominant familial Beh\u00e7et disease and haploinsufficiency A20: a review of the literature. Autoimmun Rev 17: 809-815, 2018.","DOI":"10.1016\/j.autrev.2018.02.012"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kacar M, Pathak S, Savic S. Hereditary systemic autoinflammatory diseases and Schnitzler&apos;s syndrome. Rheumatology (Oxford) 58 (Suppl 6): vi31-vi43, 2019.","DOI":"10.1093\/rheumatology\/kez448"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. \u00d6zen S, Batu ED, Demir S. Familial Mediterranean fever: recent developments in pathogenesis and new recommendations for management. Front Immunol 8: 253, 2017.","DOI":"10.3389\/fimmu.2017.00253"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Migita K, Agematsu K, Yazaki M, et al. Familial Mediterranean fever: genotype-phenotype correlations in Japanese patients. Medicine 93: 158-164, 2014.","DOI":"10.1097\/MD.0000000000000029"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Schnappauf O, Chae JJ, Kastner DL, Aksentijevich I. The pyrin inflammasome in health and disease. Front Immunol 10: 1745, 2019.","DOI":"10.3389\/fimmu.2019.01745"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Loeven NA, Medici NP, Bliska JB. The pyrin inflammasome in host-microbe interactions. Curr Opin Microbiol 54: 77-86, 2020.","DOI":"10.1016\/j.mib.2020.01.005"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Jamilloux Y, Lefeuvre L, Magnotti F, et al. Familial Mediterranean fever mutations are hypermorphic mutations that specifically decrease the activation threshold of the Pyrin inflammasome. Rheumatology 57: 100-111, 2018.","DOI":"10.1093\/rheumatology\/kex373"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Moghaddas F, Llamas R, De Nardo D, et al. A novel pyrin-associated autoinflammation with neutrophilic dermatosis mutation further defines 14-3-3 binding of pyrin and distinction to familial Mediterranean fever. Ann Rheum Dis 76: 2085-2094, 2017.","DOI":"10.1136\/annrheumdis-2017-211473"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Giancane G, Ter Haar NM, Wulffraat N, et al. Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever. Ann Rheum Dis 74: 635-641, 2017.","DOI":"10.1136\/annrheumdis-2014-206844"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. G\u00fcl A. Approach to the patients with inadequate response to colchicine in familial Mediterranean fever. Best Pract Res Clin Rheumatol 30: 296-303, 2016.","DOI":"10.1016\/j.berh.2016.09.001"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Soriano A, Verecchia E, Afeltra A, Landolfi R, Manna R. IL-1\u03b2 biological treatment of familial Mediterranean fever. Clin Rev Allergy Immunol 45: 117-130, 2013.","DOI":"10.1007\/s12016-013-8358-y"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Sakane T, Takeno M, Suzuki N, Inaba G. Beh\u00e7et&apos;s disease. N Engl J Med 341: 1284-1291, 1999.","DOI":"10.1056\/NEJM199910213411707"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kirino Y, Bertsias G, Ishigatsubo Y, et al. Genome-wide association analysis identifies new susceptibility loci for Beh\u00e7et&apos;s disease and epistasis between <i>HLA-B*51<\/i> and <i>ERAP1<\/i>. Nat Genet 45: 202-207, 2013.","DOI":"10.1038\/ng.2520"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Perazzio SF, Allenspach EJ, Eklund KK, et al. Beh\u00e7et disease (BD) and BD-like clinical phenotypes: NF-\u03baB pathway in mucosal ulcerating diseases. Scand J Immunol 92: e12973, 2020.","DOI":"10.1111\/sji.12973"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Tong B, Liu X, Xiao J, Su G. Immunopathogenesis of Behcet&apos;s disease. Front Immunol 10: 665, 2019.","DOI":"10.3389\/fimmu.2019.00665"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kirino Y, Nakajima H. Clinical and genetic aspects of Beh\u00e7et&apos;s disease in Japan. Intern Med 58: 1199-1207, 2019.","DOI":"10.2169\/internalmedicine.2035-18"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Takeuchi M, Mizuki N, Meguro A, et al. Dense genotyping of immune-related loci implicates host responses to microbial exposure in Beh\u00e7et&apos;s disease susceptibility. Nat Genet 49: 438-443, 2017.","DOI":"10.1038\/ng.3786"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Yildiz M, Haslak F, Adrovic A, et al. Pediatric Beh\u00e7et&apos;s Disease. Front Med 8: 627192, 2021.","DOI":"10.3389\/fmed.2021.627192"},{"key":"25","unstructured":"25. Zhou Q, Wang H, Schwartz DM, et al. Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nat Genet 48: 67-73, 2018."},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Asano T, Sato S, Furuya MY, et al. Intestinal Beh\u00e7et disease associated with myelodysplastic syndrome accompanying trisomy 8 successfully treated with abdominal surgery followed by hematopoietic stem cell transplantation: a case report. Medicine 98: e17979, 2019.","DOI":"10.1097\/MD.0000000000017979"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Chen Y, Ye Z, Chen L, et al. Association of clinical phenotypes in haploinsufficiency A20 (HA20) with disrupted domains of A20. Front Immunol 11: 574992, 2020.","DOI":"10.3389\/fimmu.2020.574992"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Wu Y, He X, Huang N, Yu J, Shao B. A20: a master regulator of arthritis. Arthritis Res Ther 22: 220, 2020.","DOI":"10.1186\/s13075-020-02281-1"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Tsuchida N, Kirino Y, Soejima Y, et al. Haploinsufficiency of A20 caused by a novel nonsense variant or entire deletion of TNFAIP3 is clinically distinct from Beh\u00e7et&apos;s disease. Arthritis Res Ther 21: 137, 2019.","DOI":"10.1186\/s13075-019-1928-5"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Kadowaki S, Hashimoto K, Nishimura T, et al. Functional analysis of novel A20 variants in patients with atypical inflammatory diseases. Arthritis Res Ther 23: 52, 2021.","DOI":"10.1186\/s13075-021-02434-w"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Sato S, Fujita Y, Shigemura T, et al. Juvenile onset autoinflammatory disease due to a novel mutation in TNFAIP3 (A20). Arthritis Res Ther 20: 274, 2018.","DOI":"10.1186\/s13075-018-1766-x"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Sloand EM, Kim S, Fuhrer M, et al. Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities. Blood 100: 4427-4432, 2002.","DOI":"10.1182\/blood-2002-01-0096"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Ahn JK, Cha HS, Koh EM, et al. Behcet&apos;s disease associated with bone marrow failure in Korean patients: clinical characteristics and the association of intestinal ulceration and trisomy 8. Rheumatology 47: 1228-1230, 2008.","DOI":"10.1093\/rheumatology\/ken162"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Shen Y, Ma HF, Luo D, Cai JF, Zou J, Guan JL. High incidence of gastrointestinal ulceration and cytogenetic aberration of trisomy 8 as typical features of Beh\u00e7et&apos;s disease associated with myelodysplastic syndrome: a series of 16 consecutive Chinese patients from the Shanghai Beh\u00e7et&apos;s disease database and comparison with the literature. Biomed Res Int 2018: 8535091, 2018.","DOI":"10.1155\/2018\/8535091"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K. Cytokine profile in Beh\u00e7et&apos;s disease patients. Relationship with disease activity. Scand J Rheumatol 31: 205-210, 2002.","DOI":"10.1080\/030097402320318387"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Hasegawa H, Iwamasa K, Hatta N, Fujita S. Beh\u00e7et&apos;s disease associated with myelodysplastic syndrome with elevated levels of inflammatory cytokines. Mod Rheumatol 13: 350-355, 2003.","DOI":"10.3109\/s10165-003-0245-6"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Chen G, Zeng W, Miyazato A, et al. Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood 104: 4210-4218, 2004.","DOI":"10.1182\/blood-2004-01-0103"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Shimizu H, Sato S, Suzuki T, et al. Intestinal Beh\u00e7et&apos;s disease complicated by myelodysplastic syndrome and secondary pulmonary alveolar proteinosis: a case report. BMC Gastroenterol 21: 488, 2021.","DOI":"10.1186\/s12876-021-02065-0"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Beh\u00e7et disease. Ann Rheum Dis 67: 1656-1662, 2008.","DOI":"10.1136\/ard.2007.080432"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Kimura M, Tsuji Y, Iwai M, et al. Usefulness of adalimumab for treating a case of intestinal Beh\u00e7et&apos;s disease with trisomy 8 myelodysplastic syndrome. Intest Res 13: 166-169, 2015.","DOI":"10.5217\/ir.2015.13.2.166"},{"key":"41","doi-asserted-by":"publisher","unstructured":"41. Soysal T, Saliho\u011flu A, Esato\u011flu SN, et al. Bone marrow transplantation for Beh\u00e7et&apos;s disease: a case report and systematic review of the literature. Rheumatology 53: 1136-1141, 2014.","DOI":"10.1093\/rheumatology\/ket479"},{"key":"42","doi-asserted-by":"publisher","unstructured":"42. Toyonaga T, Nakase H, Matsuura M, et al. Refractoriness of intestinal Beh\u00e7et&apos;s disease with myelodysplastic syndrome involving trisomy 8 to medical therapies - our case experience and review of the literature. Digestion 88: 217-221, 2013.","DOI":"10.1159\/000355341"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Bywaters EG. Still&apos;s disease in the adult. Ann Rheum Dis 30: 121-133, 1971.","DOI":"10.1136\/ard.30.2.121"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still&apos;s disease. Nat Rev Rheumatol 14: 603-618, 2018.","DOI":"10.1038\/s41584-018-0081-x"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Asano T, Furukawa H, Sato S, et al. Effects of HLA-DRB1 alleles on susceptibility and clinical manifestations in Japanese patients with adult onset Still&apos;s disease. Arthritis Res Ther 19: 199, 2017.","DOI":"10.1186\/s13075-017-1406-x"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Fujita Y, Furukawa H, Asano T, et al. HLA-DQB1 DPB1 alleles in Japanese patients with adult-onset Still&apos;s disease. Mod Rheumatol 29: 843-847, 2019.","DOI":"10.1080\/14397595.2018.1514999"},{"key":"47","doi-asserted-by":"publisher","unstructured":"47. Nonaka F, Migita K, Jiuchi Y, et al. Increased prevalence of <i>MEFV<\/i> exon 10 variants in Japanese patients with adult-onset Still&apos;s disease. Clin Exp Immunol 179: 392-397, 2015.","DOI":"10.1111\/cei.12463"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Tomaras S, Goetzke CC, Kallinich T, Feist E. Adult-onset Still&apos;s disease: clinical aspects and therapeutic approach. J Clin Med 10: 733, 2021.","DOI":"10.3390\/jcm10040733"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Nariai Y, Kamino H, Obayashi E, et al. Generation and characterization of antagonistic anti-human interleukin (IL)-18 monoclonal antibodies with high affinity: two types of monoclonal antibodies against full-length IL-18 and the neoepitope of inflammatory caspase-cleaved active IL-18. Arch Biochem Biophys 663: 71-82, 2019.","DOI":"10.1016\/j.abb.2019.01.001"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Han G, Chen G, Shen B, Li Y. Tim-3: An activation marker and activation limiter of innate immune cells. Front Immunol 4: 449, 2013.","DOI":"10.3389\/fimmu.2013.00449"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Fujita Y, Asano T, Matsumoto H, et al. Elevated serum levels of checkpoint molecules in patients with adult Still&apos;s disease. Arthritis Res Ther 22: 174, 2020.","DOI":"10.1186\/s13075-020-02263-3"},{"key":"52","unstructured":"52. Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still&apos;s disease. J Rheumatol 19: 424-430, 1992."},{"key":"53","unstructured":"53. Chen DY, Lan JL, Lin FJ, Hsieh TY. Pro-inflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still&apos;s disease. J Rheumatol 31: 2189-2198, 2004."},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult onset Still&apos;s disease. J Autoimmun 93: 24-36, 2018.","DOI":"10.1016\/j.jaut.2018.07.018"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Wang R, Li T, Ye S, et al. Macrophage activation syndrome associated with adult-onset Still&apos;s disease: a multicenter retrospective analysis. Clin Rheumatol 39: 2379-2386, 2020.","DOI":"10.1007\/s10067-020-04949-0"},{"key":"56","unstructured":"56. Schnitzler L, Schubert B, Boasson M, et al. Urticaire chronique, l\u00e9sions osseuses, macroglobulin\u00e9mie IgM: maladie de Waldenstr\u00f6m? 2\u00e8me pr\u00e9sentation. Bull Soc Fr Dermatol Syphil 81: 363, 1974."},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Gusdorf L, Asli B, Barbarot S, et al. Schnitzler syndrome: validation and applicability of diagnostic criteria in real-life patients. Allergy 72: 177-182, 2017.","DOI":"10.1111\/all.13035"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Niederhauser BD, Dingli D, Kyle RA, Ringler MD. Imaging findings in 22 cases of Schnitzler syndrome: characteristic para-articular osteosclerosis, and the &quot;hot knees&quot; sign differential diagnosis. Skeletal Radiol 43: 905-915, 2014.","DOI":"10.1007\/s00256-014-1857-y"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Lipsker D, Veran Y, Grunenberger F, Cribier B, Heid E, Grosshans E. The Schnitzler syndrome: four new cases and review of the literature. Medicine 80: 37-44, 2001.","DOI":"10.1097\/00005792-200101000-00004"},{"key":"60","doi-asserted-by":"publisher","unstructured":"60. Simon A, Asli B, Braun-Falco M, et al. Schnitzler&apos;s syndrome: diagnosis, treatment, and follow-up. Allergy 68: 562-568, 2013.","DOI":"10.1111\/all.12129"},{"key":"61","unstructured":"61. Machet L, Vaillant L, Machet MC, Reisenleiter M, Goupille P, Lorette G. Schnitzler&apos;s syndrome (urticaria and macroglobulinemia): evolution to Waldenstr\u00f6m&apos;s disease is not uncommon. Acta Derm Venereol 76: 413, 1996."},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Claes K, Bammens B, Delforge M, Evenepoel P, Kuypers D, Vanrenterghem Y. Another devastating complication of the Schnitzler syndrome: AA amyloidosis. Br J Dermatol 158: 182-184, 2008.","DOI":"10.1111\/j.1365-2133.2007.08251.x"},{"key":"63","unstructured":"63. Varella TC, Nishimura MY, Machado MC, de Moraes-Vasconcelos D, Rivitti EA. Schnitzler&apos;s syndrome without monoclonal gammopathy. Acta Derm Venereol 85: 272-273, 2005."},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Fujita Y, Asano T, Sakai A, et al. A case of Schnitzler&apos;s syndrome without monoclonal gammopathy successfully treated with canakinumab. BMC Musculoskelet Disord 22: 257, 2021.","DOI":"10.1186\/s12891-021-04120-z"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. de Koning HD, Schalkwijk J, Stoffels M, et al. The role of interleukin-1 beta in the pathophysiology of Schnitzler&apos;s syndrome. Arthritis Res Ther 17: 187, 2015.","DOI":"10.1186\/s13075-015-0696-0"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Bixio R, Rossini M, Giollo A. Efficacy of interleukin-1 blockade in Schnitzler&apos;s syndrome without detectable monoclonal gammopathy: a case-based review. Clin Rheumatol 40: 2973-2977, 2021.","DOI":"10.1007\/s10067-020-05501-w"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/1\/62_09279-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T03:22:36Z","timestamp":1673061756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/1\/62_09279-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,1]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.09279-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,1]]},"article-number":"09279-21"}}